Your browser doesn't support javascript.
loading
In vitro and in vivo effects of 2,4 diaminoquinazoline inhibitors of the decapping scavenger enzyme DcpS: Context-specific modulation of SMN transcript levels.
Cherry, Jonathan J; DiDonato, Christine J; Androphy, Elliot J; Calo, Alessandro; Potter, Kyle; Custer, Sara K; Du, Sarah; Foley, Timothy L; Gopalsamy, Ariamala; Reedich, Emily J; Gordo, Susana M; Gordon, William; Hosea, Natalie; Jones, Lyn H; Krizay, Daniel K; LaRosa, Gregory; Li, Hongxia; Mathur, Sachin; Menard, Carol A; Patel, Paraj; Ramos-Zayas, Rebeca; Rietz, Anne; Rong, Haojing; Zhang, Baohong; Tones, Michael A.
Afiliación
  • Cherry JJ; Rare Disease Research Unit, Pfizer Worldwide Research and Development, Cambridge, Massachusetts, United States of America.
  • DiDonato CJ; Department of Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America.
  • Androphy EJ; Human Molecular Genetics Program, Ann & Robert Lurie Children's Hospital, Stanley Manne Research Institute, Chicago, Illinois, United States of America.
  • Calo A; Department of Dermatology, Indiana University School of Medicine, Indianapolis, Indiana, United States of America.
  • Potter K; Rare Disease Research Unit, Pfizer Worldwide Research and Development, Cambridge, Massachusetts, United States of America.
  • Custer SK; Department of Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America.
  • Du S; Human Molecular Genetics Program, Ann & Robert Lurie Children's Hospital, Stanley Manne Research Institute, Chicago, Illinois, United States of America.
  • Foley TL; Department of Dermatology, Indiana University School of Medicine, Indianapolis, Indiana, United States of America.
  • Gopalsamy A; Precision Medicine, Pfizer Worldwide Research and Development, Cambridge, Massachusetts, United States of America.
  • Reedich EJ; Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Groton, Connecticut, United States of America.
  • Gordo SM; Primary Pharmacology Group, Pfizer Worldwide Research and Development, Groton, Connecticut, United States of America.
  • Gordon W; Medicine Design, Pfizer Worldwide Research and Development, Cambridge, Massachusetts, United States of America.
  • Hosea N; Department of Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America.
  • Jones LH; Human Molecular Genetics Program, Ann & Robert Lurie Children's Hospital, Stanley Manne Research Institute, Chicago, Illinois, United States of America.
  • Krizay DK; Rare Disease Research Unit, Pfizer Worldwide Research and Development, Cambridge, Massachusetts, United States of America.
  • LaRosa G; Precision Medicine, Pfizer Worldwide Research and Development, Cambridge, Massachusetts, United States of America.
  • Li H; Pharmacokinetics and Drug Metabolism, Pfizer Worldwide Research and Development, Cambridge, Massachusetts, United States of America.
  • Mathur S; Medicine Design, Pfizer Worldwide Research and Development, Cambridge, Massachusetts, United States of America.
  • Menard CA; Rare Disease Research Unit, Pfizer Worldwide Research and Development, Cambridge, Massachusetts, United States of America.
  • Patel P; Rare Disease Research Unit, Pfizer Worldwide Research and Development, Cambridge, Massachusetts, United States of America.
  • Ramos-Zayas R; Department of Dermatology, Indiana University School of Medicine, Indianapolis, Indiana, United States of America.
  • Rietz A; Business Technology, Pfizer Worldwide Research and Development, Cambridge, Massachusetts, United States of America.
  • Rong H; Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Groton, Connecticut, United States of America.
  • Zhang B; Primary Pharmacology Group, Pfizer Worldwide Research and Development, Groton, Connecticut, United States of America.
  • Tones MA; Rare Disease Research Unit, Pfizer Worldwide Research and Development, Cambridge, Massachusetts, United States of America.
PLoS One ; 12(9): e0185079, 2017.
Article en En | MEDLINE | ID: mdl-28945765
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Quinazolinas / Atrofia Muscular Espinal / Endorribonucleasas / Inhibidores Enzimáticos Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans / Male Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Quinazolinas / Atrofia Muscular Espinal / Endorribonucleasas / Inhibidores Enzimáticos Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans / Male Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos